SMC1A (Ab-957) Antibody

What is the epitope specificity of SMC1A (Ab-957) Antibody compared to phospho-specific variants?

SMC1A (Ab-957) Antibody recognizes the peptide sequence around amino acids 955-959 (G-S-S-Q-G) derived from Human SMC1A, detecting endogenous total SMC1A protein regardless of modification status . In contrast, phospho-specific antibodies such as anti-SMC1A (pSer957) specifically recognize SMC1A only when phosphorylated at Ser957 . This distinction is critical when designing experiments to monitor phosphorylation events.

When selecting between these antibodies, researchers should consider whether their experimental question concerns total protein expression or specifically the phosphorylated form involved in particular cellular functions.

What are the validated applications for SMC1A (Ab-957) and (pSer957) antibodies?

The applications for SMC1A antibodies vary based on their specific epitope recognition:

For total SMC1A (Ab-957) antibodies:

• Western Blotting (WB) - Detects a band at approximately 143-160 kDa

• Immunohistochemistry (IHC) - Primarily nuclear staining pattern

For phospho-specific SMC1A (pSer957) antibodies:

• Western Blotting (WB) - Detects phosphorylated form at 160 kDa

• Immunohistochemistry (IHC) - Nuclear pattern with cell cycle-dependent intensity

• Immunoprecipitation (IP) - Typically using 0.5-4 μg antibody per 200-400 μg of cell extract

• ELISA - Typically at 1 μg/ml concentration

• Immunofluorescence (IF) - Allows co-localization studies with other proteins

These applications have been validated across multiple tissue types, particularly in cancer research contexts including colorectal, breast, and esophageal cancer models .

How should Western blotting protocols be optimized for detecting phosphorylated SMC1A (pSer957)?

Successful detection of phosphorylated SMC1A requires specific methodological considerations:

• Sample preparation:

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers

  • Process samples quickly at 4°C to prevent dephosphorylation

  • Use RIPA or NP-40 buffer supplemented with protease inhibitors for effective extraction

• Gel electrophoresis and transfer:

  • Use 6-8% gels for better resolution of high molecular weight SMC1A (160 kDa)

  • Perform wet transfer at 30V overnight at 4°C for high molecular weight proteins

  • Use 0.45 μm PVDF membranes for optimal protein binding

• Antibody incubation:

  • Block with 5% BSA in TBST (important for phospho-epitopes, milk contains phosphatases)

  • Dilute pSer957-specific antibodies 1:500-1:2000

  • Incubate primary antibody overnight at 4°C with gentle agitation

  • Include both total SMC1A and pSer957 antibodies on parallel blots for ratio analysis

• Controls:

  • Include lambda phosphatase-treated samples as negative controls

  • Use cell lysates from models with known SMC1A phosphorylation status (HCT116 cells)

  • Consider ATM inhibitor-treated samples to reduce phosphorylation at Ser957

This optimization is essential as variations in phosphorylation of SMC1A at Ser957 have significant biological implications in cancer progression and therapeutic response .

What methodological approaches enable accurate analysis of SMC1A phosphorylation throughout the cell cycle?

To effectively analyze cell cycle-dependent SMC1A phosphorylation:

• Cell synchronization methods:

  • G1/S boundary: Double thymidine block or aphidicolin treatment

  • G2/M phase: Nocodazole treatment (100 ng/mL for 16 hours)

  • M phase: Mitotic shake-off after nocodazole release

• Multi-parameter analysis:

  • Western blotting: Probe for pSer957 SMC1A, total SMC1A, and cell cycle markers

  • Immunofluorescence: Co-stain for pSer957 SMC1A with cyclin B1 (M phase) and phospho-histone H3 (Ser10)

  • Flow cytometry: Combine DNA content analysis with intracellular SMC1A staining

• Data interpretation guidelines:

  • Calculate phosphorylation ratio (pSer957/total SMC1A) at each time point

  • Track chromatin association patterns during different cell cycle phases

  • Compare with expected patterns: pSer957 SMC1A associates with chromatin during G1/S/G2 phases but not during M phase

Research has demonstrated that phosphorylated SMC1A at Ser957 and Ser966 stimulates binding to Rae1 during mitosis, which is required for bipolar spindle formation . The phosphorylated form on Ser957 associates with chromatin during G1/S/G2 phases but not during M phase, suggesting this modification plays a regulatory role rather than directly controlling cohesin function .

How can I optimize immunohistochemistry protocols for SMC1A (pSer957) antibodies in tissue samples?

For robust IHC results with phospho-specific SMC1A antibodies:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Avoid overfixation which can mask phospho-epitopes

  • Embed in paraffin and section at 4-5 μm thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval is essential for phospho-epitopes

  • Test both citrate buffer (pH 6.0) and EDTA buffer (pH 8.0)

  • Boil sections for 15-20 minutes followed by 20 minutes cooling

• Antibody dilution and incubation:

  • For pSer957 antibodies: Use 1:50-1:200 dilution range

  • Block with 5% BSA or commercial protein block

  • Incubate primary antibody overnight at 4°C

  • Use appropriate detection systems (HRP/DAB or fluorescent secondaries)

• Controls and validation:

  • Include known positive controls (breast cancer, esophageal cancer tissues)

  • Use competing phospho-peptide as specificity control

  • Compare with serial sections stained for total SMC1A

Research has shown that pSer957 SMC1A levels are significantly elevated in colorectal, breast, and esophageal carcinomas compared to adjacent normal tissues , making this optimization crucial for accurate assessment of clinical samples.

How can SMC1A (pSer957) antibodies be used to investigate the interplay between phosphorylation and acetylation of SMC1A?

To study the reciprocal relationship between SMC1A post-translational modifications:

• Sequential immunoprecipitation approach:

  • First IP: Use anti-SMC1A (pSer957) antibody

  • Elute and perform second IP with anti-acetyl-lysine antibody

  • Analyze by Western blot with total SMC1A antibody

  • Quantify relative abundance of dual-modified protein

• Pharmacological modulation:

  • SIRT2 inhibition with AGK2 increases K579 acetylation and reduces Ser957 phosphorylation

  • Monitor both modifications after treatment using specific antibodies

  • Analyze functional consequences (mitotic spindle formation, apoptosis markers)

• Mutational analysis:

  • Compare wild-type SMC1A, K579Q (acetylmimetic), and K579Q-DD (acetylmimetic with phosphomimetic) mutants

  • Assess phosphorylation status with pSer957 antibodies

  • Correlate with functional outcomes (cell survival, tumor growth)

Research has demonstrated that K579 acetylation of SMC1A inhibits its phosphorylation at Ser957, promoting mitotic catastrophe and enhancing chemosensitivity . The acetylmimetic SMC1A K579Q mutant showed significantly reduced SMC1A phosphorylation compared to wild-type, resulting in lower tumor volume and weight in xenograft models .

What methodological approaches can detect the role of SMC1A phosphorylation in tumor immune microenvironment?

To investigate SMC1A's influence on the tumor immune landscape:

• Multiplex immunohistochemistry:

  • Create sequential staining panels with SMC1A, pSer957-SMC1A, and immune markers

  • Include CD45 (pan-immune), CD4 (T helper cells), FoxP3 (Tregs)

  • Perform digital image analysis for spatial relationships

  • Quantify co-localization patterns

• Flow cytometry of tumor-infiltrating lymphocytes:

  • Digest tumor tissue to single-cell suspension

  • Surface stain for immune markers

  • Fix, permeabilize, and stain for intracellular pSer957 SMC1A

  • Analyze immune cell subsets for SMC1A phosphorylation

• Correlation with immune checkpoint molecules:

  • Assess relationship between SMC1A phosphorylation and CD274 (PD-L1), CTLA4, PDCD1 (PD-1)

  • Evaluate predictive potential for immunotherapy response

Research has demonstrated that SMC1A expression positively correlates with immune cell infiltration in colorectal cancer . In mouse models, SMC1A overexpression was associated with increased percentages of IL4+CD4+ T cells (Th2) and FoxP3+CD4+ T cells (Tregs), suggesting SMC1A may influence the immune microenvironment toward an immunosuppressive phenotype .

How can I apply SMC1A (pSer957) antibodies to evaluate therapeutic responses in cancer models?

For investigating SMC1A phosphorylation as a biomarker of treatment response:

• Treatment response assessment protocol:

  • Obtain pre-treatment baseline samples

  • Collect specimens at defined intervals during treatment

  • Process immediately to preserve phosphorylation status

  • Analyze by both IHC and Western blotting

• Chemotherapy sensitivity correlation:

  • Monitor pSer957 SMC1A levels during 5-FU or oxaliplatin treatment

  • Compare with apoptotic markers (cleaved PARP, cleaved caspase-3)

  • Assess relationship with SIRT2 expression (mediates deacetylation)

• Predictive biomarker development:

  • Stratify samples based on pSer957/total SMC1A ratio

  • Correlate with treatment outcomes

  • Evaluate potential as companion diagnostic

Research has shown that K579 acetylation of SMC1A (which inhibits Ser957 phosphorylation) significantly enhances sensitivity to chemotherapeutic agents, with cells expressing acetylmimetic SMC1A showing significantly inhibited survival at lower doses of oxaliplatin or 5-FU . This suggests that monitoring SMC1A phosphorylation status may help predict therapeutic response.

How should researchers interpret changes in SMC1A phosphorylation at Ser957 in cancer versus normal tissues?

When analyzing SMC1A phosphorylation patterns across tissue types:

• Comparative analysis framework:

  • Examine matched tumor-normal pairs from the same patient

  • Quantify staining intensity using standardized scoring systems

  • Calculate phosphorylation ratio (pSer957/total SMC1A)

  • Consider regional heterogeneity within tumors

• Multi-modification context:

  • Evaluate in relation to K579 acetylation status

  • Consider SIRT2 expression levels (mediates deacetylation)

  • Assess correlation with proliferation markers (Ki-67)

• Clinical correlation guidelines:

  • Higher pSer957 SMC1A in tumors suggests increased proliferative capacity

  • Decreased K579 acetylation with increased pSer957 indicates potential chemoresistance

  • Regional variations may reveal distinct microenvironmental interactions

Research has demonstrated a consistent pattern across multiple cancer types: pSer957 SMC1A levels are significantly elevated while K579 acetylation is reduced in colorectal, breast, and esophageal carcinomas compared to adjacent normal tissues . These alterations correlate with SIRT2 upregulation and suggest a mechanistic link between deacetylation and phosphorylation in promoting tumor cell survival .

What is the functional significance of SMC1A phosphorylation at Ser957 in chromosome dynamics and mitosis?

The phosphorylation of SMC1A at Ser957 plays critical roles in chromosome biology:

• Chromatin association dynamics:

  • Phosphorylated form associates with chromatin during G1/S/G2 phases

  • Dissociates during M phase, unlike total cohesin complexes

  • Forms part of the functional centromere-kinetochore complex during mitosis

• Mitotic spindle regulation:

  • Phosphorylation of Ser957 and Ser966 stimulates binding to Rae1 during mitosis

  • This interaction is required for bipolar spindle formation

  • Impaired phosphorylation leads to spindle multipolarity and mitotic catastrophe

• Sister chromatid cohesion:

  • Contributes to proper cohesion, prerequisite for chromosome segregation

  • Helps maintain genomic stability during cell division

  • Functions as part of the cohesin complex with SMC3 and RAD21

Research has demonstrated that acetylation of SMC1A at K579 inhibits its phosphorylation at Ser957, reducing SMC1A-Rae1 interaction and promoting multipolar spindle formation, which ultimately leads to mitotic catastrophe and apoptosis . This mechanism helps explain how altered post-translational modifications of SMC1A contribute to cancer progression.

How does SMC1A phosphorylation status relate to cancer stem cell properties and immune checkpoint expression?

The relationship between SMC1A modifications and cancer stemness/immune regulation:

• Cancer stem cell correlation:

  • High SMC1A phosphorylation positively correlates with stemness markers

  • May contribute to therapy resistance mechanisms

  • Potentially influences tumor-initiating capacity and recurrence

• Immune checkpoint relationship:

  • SMC1A positively correlates with immune checkpoint genes CD274 (PD-L1), CTLA4, and PDCD1 (PD-1)

  • Associated with "hot" T-cell inflammatory microenvironment in colon cancer

  • May influence response to immune checkpoint inhibitor therapy

• Integrated pathway analysis:

  • SMC1A potentially functions as a "bidirectional target switch"

  • Simultaneously regulates tumor-intrinsic properties (stemness) and tumor-extrinsic factors (immune microenvironment)

  • Offers potential as both a biomarker and therapeutic target

Research has demonstrated that SMC1A serves as a potential biomarker for predicting response to immune checkpoint inhibitor therapy . Its dual role in regulating both cancer stem cells and the immune microenvironment makes it a particularly interesting target for investigation in the context of treatment resistance and immunotherapy response.

What controls should be included when using phospho-specific SMC1A (pSer957) antibodies to ensure signal specificity?

To validate phospho-specific antibody signals:

• Essential experimental controls:

  • Phosphatase treatment: Treat duplicate samples with lambda phosphatase to eliminate phospho-specific signal

  • Peptide competition: Pre-incubate antibody with immunizing phospho-peptide to block specific binding

  • Genetic validation: Use SMC1A knockdown cells to confirm signal specificity

  • ATM inhibition: Treat cells with ATM inhibitors to reduce phosphorylation at Ser957

• Sample processing validation:

  • Process samples with and without phosphatase inhibitors to demonstrate protection of modification

  • Prepare nuclear and cytoplasmic fractions separately to confirm subcellular localization

  • Include positive control cell lines with known high pSer957 levels (such as HCT116)

• Technical verification:

  • Confirm correct molecular weight (~160 kDa, higher than calculated 143 kDa due to modifications)

  • Verify expected nuclear localization pattern in immunostaining

  • Compare results between different detection methods (WB vs. IHC vs. IP)

These controls are essential as phospho-specific antibodies can sometimes cross-react with similar phospho-epitopes or give false-negative results if phosphorylation is lost during sample processing.

What are the most common technical issues when using SMC1A (pSer957) antibodies and how can they be resolved?

Common challenges and their solutions:

• Weak or absent signal:

  • Issue: Rapid dephosphorylation during sample preparation

  • Solution: Use phosphatase inhibitor cocktails in all buffers; keep samples cold; process quickly

  • Issue: Inefficient extraction from nuclear compartment

  • Solution: Use nuclear extraction protocols; sonicate samples; increase detergent concentration

  • Issue: Poor transfer of high molecular weight protein

  • Solution: Use extended transfer time; lower percentage gels; add SDS to transfer buffer

• High background:

  • Issue: Non-specific binding

  • Solution: Optimize blocking (5% BSA, 5% normal goat serum); increase washing steps; use higher antibody dilution

  • Issue: Cross-reactivity with similar phospho-epitopes

  • Solution: Pre-absorb antibody with non-phosphorylated peptide; increase stringency of washing

• Inconsistent results across experiments:

  • Issue: Phosphorylation varies with cell cycle and stress

  • Solution: Standardize growth conditions; synchronize cells; control stress factors

  • Issue: Antibody lot-to-lot variation

  • Solution: Validate each new lot against known positive controls; maintain reference samples

By implementing these troubleshooting approaches, researchers can generate more reliable and reproducible data when studying SMC1A phosphorylation in various experimental contexts.